Novartis AG (NYSE: NVS) announced Monday that it is adding to its immunomodulatory medicine portfolio with with an acquisition. What Happened Novartis said it's acquiring IFM Tre, a subsidiary of IFM ...

It’s been a busy year for IFM Therapeutics. After selling off a subsidiary to Novartis and enlisting the Big Pharma as a partner for another unit, the company is promoting its R&D chief Martin Seidel, ...

Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech ...

Novartis has agreed to acquire a subsidiary of IFM Therapeutics for up to $1.575 billion, IFM said today, in a deal that will expand the pharma giant’s pipeline with one clinical and two pre-clinical ...

HOUSTON, Dec. 16, 2013 /PRNewswire/ — Freeport LNG Expansion, L.P. (Freeport LNG) and IFM Investors today announced that IFM Investors has entered into an agreement to invest approximately $1.3 ...

Just five months after Novartis put down $310 million for IFM Therapeutics’ inflammation-focused unit, the Big Pharma has come back for more. This time, it is teaming up with IFM Due, the subsidiary ...